Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer

被引：74

作者：

Sasaki, Takashi ^{[1
]}

Isayama, Hiroyuki ^{[1
]}

Nakai, Yousuke ^{[1
]}

Ito, Yukiko ^{[2
]}

Kogure, Hirofumi ^{[3
]}

Togawa, Osamu ^{[4
]}

Toda, Nobuo ^{[5
]}

Yasuda, Ichiro ^{[6
]}

Hasebe, Osamu ^{[7
]}

Maetani, Iruru ^{[8
]}

Sasahira, Naoki ^{[1
]}

Hirano, Kenji ^{[1
]}

Tsujino, Takeshi ^{[1
]}

Tada, Minoru ^{[1
]}

Omata, Masao ^{[1
]}

机构：

[1] Univ Tokyo, Dept Gastroenterol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan

[2] Japanese Red Cross Med Ctr, Dept Gastroenterol, Tokyo, Japan

[3] Kanto Cent Hosp, Dept Gastroenterol, Tokyo, Japan

[4] JR Tokyo Gen Hosp, Dept Gastroenterol, Tokyo, Japan

[5] Mitsui Mem Hosp, Dept Gastroenterol, Tokyo 101, Japan

[6] Gifu Univ Hosp, Dept Gastroenterol, Gifu, Japan

[7] Nagano Municipal Hosp, Dept Gastroenterol, Nagano, Japan

[8] Toho Univ, Ohashi Med Ctr, Dept Gastroenterol, Tokyo, Japan

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2010年 / 65卷 / 06期

基金：

日本学术振兴会;

关键词：

Biliary tract cancer; Gemcitabine; S-1; Chemotherapy; METASTATIC PANCREATIC-CANCER; 1ST-LINE CHEMOTHERAPY; CLINICAL-TRIALS; PLUS CISPLATIN; CAPECITABINE; OXALIPLATIN; CARCINOMA; ADENOCARCINOMA; MONOTHERAPY; SYSTEM;

D O I：

10.1007/s00280-009-1115-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Patients with a measurable lesion and no previous history of chemotherapy or radiotherapy were enrolled. Gemcitabine was administered intravenously at a dose of 1,000 mg/m(2) over 30 min on day 1 and 15, repeated every 4 weeks. S-1 was administered orally at a dose of 40 mg/m(2) b.i.d. on days 1-14. Tumor response was assessed every two cycles using Response Evaluation Criteria in Solid Tumors criteria. As much as 35 patients were enrolled between December 2006 and July 2008; 14 patients (40%) with gallbladder cancer and 14 (40%) with intrahepatic cholangiocarcinoma were included and 7 patients (20%) had received previous surgical resection. The overall response rate was 34.3% and the overall disease control rate was 82.9%. The median overall survival time was 11.6 months (95% CI, 7.3-15.6 months), and the median time to progression was 5.9 months (95% CI, 4.0-7.7 months). The grade 3/4 toxicities were leucopenia (23%), neutropenia (34%), anemia (20%), thrombocytopenia (6%) and anorexia (3%). Gemcitabine and S-1 combination chemotherapy has promising efficacy and good tolerability in patients with advanced biliary tract cancer.

引用

页码：1101 / 1107

页数：7

共 36 条

[1] Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma [J].